Population
22 human heart samples (12 nonfailing hearts and 10 end-stage failing left ventricles)
Design
Other
Authors
Loading...
May indicate molecular basis for contractile impairment in end-stage HF; leaves open whether restoring alphaMyHC could be therapeutic.
The alphaMyHC protein is detectable in nonfailing human hearts but becomes effectively undetectable in end-stage heart failure, suggesting a molecular basis for diminished cardiac contractility.
Miyata et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: